Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations
Kreon<sup>®</sup> (Creon<sup>®</sup>) and Lipancrea<sup>®</sup> are pancreatic enzyme supplements indicated in the treatment of exocrine pancreatic insufficiency. In order to determine their interchangeability, an <i>in vitro</i> comparison of their ph...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/12/1570 |
| _version_ | 1797455786584047616 |
|---|---|
| author | Sven Hartmann Grazyna Rydzewska J. Enrique Domínguez-Muñoz |
| author_facet | Sven Hartmann Grazyna Rydzewska J. Enrique Domínguez-Muñoz |
| author_sort | Sven Hartmann |
| collection | DOAJ |
| description | Kreon<sup>®</sup> (Creon<sup>®</sup>) and Lipancrea<sup>®</sup> are pancreatic enzyme supplements indicated in the treatment of exocrine pancreatic insufficiency. In order to determine their interchangeability, an <i>in vitro</i> comparison of their physical properties and enzymatic activity was carried out. Capsule fill weight and particle size were also determined in order to establish their physical properties. Amylase, lipase and protease activities, lipase release at different pHs and the dissolution time of pellets were assessed for enzymatic analysis. The length range of Kreon<sup>®</sup> and Lipancrea<sup>®</sup> pellets was 1.1–2.2 mm and 1.5–2.8 mm, respectively. Protease activity was below the label claim for Lipancrea<sup>®</sup> and above for Kreon<sup>®</sup> presentations. Lipase and amylase activity were equal to or higher than the label claim in both preparations. In dissolution experiments simulating the stomach passage, significant release of lipase activity was observed for Lipancrea<sup>®</sup> (% actual activity: 41% for Lipancrea<sup>®</sup> 8000; 21% for Lipancrea<sup>®</sup> 16000) after 60 min at pH 5.0. No release of lipase activity was observed for Kreon<sup>®</sup> at that particular pH. Enzyme release for Lipancrea<sup>®</sup> at pH 6.0 was generally slower than for Kreon<sup>®</sup> and seemed to be influenced by the preceding incubation at lower pH. More than 85% of Kreon<sup>®</sup> and Lipancrea<sup>®</sup> dissolved in a pH 6.0 phosphate buffer within 20 min. Despite the similarities of the enzyme content on the respective labels, Kreon<sup>®</sup> and Lipancrea<sup>®</sup> differ in pellet size, enzymatic activity and release. This may impact their therapeutic efficacy and, therefore, may limit their interchangeability. |
| first_indexed | 2024-03-09T15:58:38Z |
| format | Article |
| id | doaj.art-b29490cb80ba49928ccbb879ddd0b7e7 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T15:58:38Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-b29490cb80ba49928ccbb879ddd0b7e72023-11-24T17:17:28ZengMDPI AGPharmaceuticals1424-82472022-12-011512157010.3390/ph15121570Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin PreparationsSven Hartmann0Grazyna Rydzewska1J. Enrique Domínguez-Muñoz2Viatris Healthcare GmbH, Freundallee 9A, D-30173 Hannover, GermanyInflammatory Bowel Disease Unit, Clinical Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, 02-507 Warsaw, PolandDepartment of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, SpainKreon<sup>®</sup> (Creon<sup>®</sup>) and Lipancrea<sup>®</sup> are pancreatic enzyme supplements indicated in the treatment of exocrine pancreatic insufficiency. In order to determine their interchangeability, an <i>in vitro</i> comparison of their physical properties and enzymatic activity was carried out. Capsule fill weight and particle size were also determined in order to establish their physical properties. Amylase, lipase and protease activities, lipase release at different pHs and the dissolution time of pellets were assessed for enzymatic analysis. The length range of Kreon<sup>®</sup> and Lipancrea<sup>®</sup> pellets was 1.1–2.2 mm and 1.5–2.8 mm, respectively. Protease activity was below the label claim for Lipancrea<sup>®</sup> and above for Kreon<sup>®</sup> presentations. Lipase and amylase activity were equal to or higher than the label claim in both preparations. In dissolution experiments simulating the stomach passage, significant release of lipase activity was observed for Lipancrea<sup>®</sup> (% actual activity: 41% for Lipancrea<sup>®</sup> 8000; 21% for Lipancrea<sup>®</sup> 16000) after 60 min at pH 5.0. No release of lipase activity was observed for Kreon<sup>®</sup> at that particular pH. Enzyme release for Lipancrea<sup>®</sup> at pH 6.0 was generally slower than for Kreon<sup>®</sup> and seemed to be influenced by the preceding incubation at lower pH. More than 85% of Kreon<sup>®</sup> and Lipancrea<sup>®</sup> dissolved in a pH 6.0 phosphate buffer within 20 min. Despite the similarities of the enzyme content on the respective labels, Kreon<sup>®</sup> and Lipancrea<sup>®</sup> differ in pellet size, enzymatic activity and release. This may impact their therapeutic efficacy and, therefore, may limit their interchangeability.https://www.mdpi.com/1424-8247/15/12/1570pancreatic enzyme supplementexocrine pancreatic insufficiencyenzyme activitypharmacokinetics<i>in vitro</i>enzyme release |
| spellingShingle | Sven Hartmann Grazyna Rydzewska J. Enrique Domínguez-Muñoz Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations Pharmaceuticals pancreatic enzyme supplement exocrine pancreatic insufficiency enzyme activity pharmacokinetics <i>in vitro</i> enzyme release |
| title | Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations |
| title_full | Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations |
| title_fullStr | Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations |
| title_full_unstemmed | Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations |
| title_short | Kreon<sup>®</sup> (Creon<sup>®</sup>) vs. Lipancrea<sup>®</sup>: <i>In Vitro</i> Comparison of Two Encapsulated Pancreatin Preparations |
| title_sort | kreon sup r sup creon sup r sup vs lipancrea sup r sup i in vitro i comparison of two encapsulated pancreatin preparations |
| topic | pancreatic enzyme supplement exocrine pancreatic insufficiency enzyme activity pharmacokinetics <i>in vitro</i> enzyme release |
| url | https://www.mdpi.com/1424-8247/15/12/1570 |
| work_keys_str_mv | AT svenhartmann kreonsupsupcreonsupsupvslipancreasupsupiinvitroicomparisonoftwoencapsulatedpancreatinpreparations AT grazynarydzewska kreonsupsupcreonsupsupvslipancreasupsupiinvitroicomparisonoftwoencapsulatedpancreatinpreparations AT jenriquedominguezmunoz kreonsupsupcreonsupsupvslipancreasupsupiinvitroicomparisonoftwoencapsulatedpancreatinpreparations |